Jessica Baker Flechtner | Chief Scientific Officer
Genocea Biosciences

Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences

Dr. Flechtner joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer. She has more than 20 years of experience in immunology, cancer, infectious disease, vaccine and cell therapy development. She leads Genocea’s efforts to develop personalized T cell-directed immunotherapies and vaccines against cancer using the company’s proprietary ATLAS™ platform. Prior to joining Genocea, Dr. Flechtner served in a variety of roles developing vaccines and immunotherapies for cancer, infectious disease and other indications. She received a B.S. in Animal Science and a Ph.D. in Cellular Immunology from Cornell University, and performed her post-doctoral work at Dana Farber Cancer Institute and Harvard Medical School. Dr. Flechtner is an inventor on many pending and issued patents and is an author of multiple peer-reviewed scientific publications. She is also a passionate advocate for STEM education for girls and young women


Festival of Biologics Day 1 @ 10:00

Keynote panel discussion: What does the future of Immunotherapy hold for Oncology and Infectious Diseases?

Festival of Biologics Day 1 @ 16:50

Unleashing the Titans: the GEN-011 Neoantigen-targeted Peripheral T cell Therapy for Solid Tumors

  • Adoptive T cell therapies have resulted in unprecedented efficacy against solid tumors
  • Prioritizing neoantigens with the ATLASTM bioassay identifies the right targets and avoids pro-tumor InhibigensTM
  • The GEN-011 neoantigentargeted peripheral T cells(NPTs) have broad specificity and are nonexhausted, polyfunctional, cytolytic cells
  • The TITAN-1 clinical trial is ongoing (NCT04596033)
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers